• News
  • SAN DIEGO
  • Finance

Boston Scientific to spend $415M on Bayer division

NATICK, Mass. (AP) -- Boston Scientific will spend $415 million to buy the Bayer division that makes treatments for diseased blood vessels outside the heart.

The Natick company said Thursday that the deal will improve its access to the more than 27 million people worldwide who have coronary and peripheral vascular disease. Bayer Interventional has about 350 employees, and its products include the AngioJet Thrombectomy system and the Fetch 2 Aspiration Catheter, which remove blood clots from blocked arteries and veins.

Bayer says the sale will allow its health care unit to focus on growing its radiology and diabetes care segments.

Boston Scientific will fold the Bayer division into its Peripheral Interventions business. It expects to close the deal in the second half of the year.

Bayer recently announced a $14.2 billion deal to buy Merck & Co.'s consumer health business, which includes Claritin allergy pills and the Coppertone skin care line.

Shares of Boston Scientific climbed 9 cents to $12.88 in premarket trading.

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.